EcoDrugPlus

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSUPAG00010007131
Gene Symbol: PSMB3
3 Cross references
234 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSUPAG00010004456
Gene Symbol: PSMB4
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSUPAG00010011210
Gene Symbol: PSMB5
1 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSUPAG00010005789
Gene Symbol: PSMB6
2 Cross references
210 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSUPAG00010013273
Gene Symbol: PSMB7
3 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSUPAG00010004745
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSUPAG00010005439
Gene Symbol: PSMB9
1 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSUPAG00010003228
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSUPAG00010004155
Gene Symbol: PSMD4
1 Cross references
282 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSUPAG00010003329
Gene Symbol: PSMC2
1 Cross references
223 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSUPAG00010013908
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSUPAG00010022554
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).